Researchers have engineered CAR-T cells with fusion proteins to target solid tumors. These engineered cells are designed to deliver localized IL-12 and may improve treatment outcomes for solid tumor cancers. The approach appears to show promise, with some reports suggesting it can safely and effectively target solid tumors, although the specifics of the therapy's design and effectiveness are still being explored.